Cargando…
Neutralizing anti-drug antibodies in Fabry disease have no obvious clinical impact?
Fabry disease (FD) is a rare X-linked disorder caused by a deficiency of lysosomal α-galactosidase A activity. Treatment with recombinant enzyme replacement therapy is available since 2001 and the effects of anti-drug antibodies (ADA) on therapy efficacy and disease outcome in affected patients have...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162957/ https://www.ncbi.nlm.nih.gov/pubmed/30268124 http://dx.doi.org/10.1186/s13023-018-0916-1 |